PRESTIGE CONSUMER HEALTHCARE INC. Net Change in Cash
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Net Change in Cash of $25.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-06-30 was $25.26M, a 39.31% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-06-30 was $41.62M.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-06-30 was -$12.21M.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-06-30 was -$3.91M, a 145.01% decline year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2026 was -$34.02M, a 166.16% decline from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $51.41M.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$12.02M, a 138.40% decline from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $31.30M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.26M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$34.02M 10-K · filed 2026-05-14 | |||
| 2025-12-31 | -$35.51M 10-Q · filed 2026-02-05 | |||
| 2025-09-30 | $21.22M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $41.62M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $51.41M 10-K · filed 2026-05-14 | |||
| 2024-12-31 | $4.41M 10-Q · filed 2026-02-05 | |||
| 2024-09-30 | $5.07M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$12.21M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$12.02M 10-K · filed 2026-05-14 | |||
| 2023-12-31 | $5.13M 10-Q · filed 2025-02-06 | |||
| 2023-09-30 | $1.58M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$3.91M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $31.30M 10-K · filed 2025-05-09 | |||
| 2022-12-31 | $59.17M 10-Q · filed 2024-02-08 | |||
| 2022-09-30 | $15.26M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $8.68M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$5.12M 10-K · filed 2024-05-15 | |||
| 2021-12-31 | -$11.28M 10-Q · filed 2023-02-02 | |||
| 2021-09-30 | $10.52M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $131.32M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$62.46M 10-K · filed 2023-05-05 | |||
| 2020-12-31 | -$32.66M 10-Q · filed 2022-02-03 | |||
| 2020-09-30 | -$68.16M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | -$36.82M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $67.23M 10-K · filed 2022-05-06 | |||
| 2019-12-31 | $1.06M 10-Q · filed 2021-02-04 | |||
| 2019-09-30 | $375.00K 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $1.51M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$5.02M 10-K · filed 2021-05-07 | |||
| 2018-12-31 | -$7.88M 10-Q · filed 2020-02-06 | |||
| 2018-09-30 | $4.36M 10-Q · filed 2019-10-31 | |||
| 2018-06-30 | $1.72M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | -$9.31M 10-K · filed 2020-05-08 | |||
| 2017-03-31 | $14.63M 10-K · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |